Studi in Silico Lima Senyawa Aktif Sebagai Penghambat Protein Virus Dengue

Reni Herman

doi:10.22435/jki.v9i1.1157

Reni Herman

DOI: https://doi.org/10.22435/jki.v9i1.1157

Keywords: Antiviral, Catechin, Mangiferin, EGCG, Quercetin

Abstract

Dengue infection is an endemic disease in the tropics and subtropics, caused by dengue virus (DENV) infection. Some compounds have been shown to have antiviral effects on some viruses. In silico study is conducted to predict the stability of natural ingredient compounds: artemisinin, catechin, mangiferin, epigallocatechin gallate (EGCG), and quercetin in their interactions with dengue virus proteins at molecular level. This study is carried out using the 2008 version of the Molecular Operating Environment (MOE) software. Ligands are ribavirin as antiviral control whereas artemisinin, mangiferin, EGCG, and quercetin with 3D mole format structures. The downloaded DENV protein with PDB document format is the DENV serotype 2 envelope protein with 1OKE code, non structural protein 3 (NS3) with 2VBC code and NS5 protein with 1L9K code. In silico test generally showed that catechin, mangiferin, EGCG, and quercetin had more stable docking ligands to DENV’s proteins. In particular, mangiferin had stable docking ligand to envelope proteins, NS3 (helicase and protease) and in NS5-methyltransferase compared to ribavirin. Catechin stabled on NS3-protease, EGCG on NS3 (helicase and protease) and quercetin on NS3-protease. Artemisinin had less stabled bonds than ribavirin. The results indicated that catechin, mangiferin, EGCG, and quercetin had potential inhibition to DENV proteins whereas mangiferin was the most potential compound to inhibit dengue virus protein targets.

References

Henchal EA, Putnak JR. The dengue viruses. Clinical Microbiology Review. 1990 Oct;3(4):376–96.

Alen MMF, Schols D. Dengue virus entry as target for antiviral therapy. Journal of Tropical Medicine. 2012;2012:1-13.

Luo D, Xu T, Hunke C, Gruber G, Vasudevan SG, Lescar J. Crystal structure of the NS3 protease-helicase from dengue virus. Journal of Virology. 2008 Jan;82(1):173–83.

Wang CC, Huang ZS, Chiang PL, Chen CT, Wu HN. Analysis of the nucleoside triphosphatase, RNA triphosphatase, and unwinding activities of the helicase domain of dengue virus NS3 protein. FEBS Letters. 2009 Feb;583(4):691–6.

Steinmann J, Buer J, Pietschmann T, Steinmann E. Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. British Journal of Pharmacology. 2013 Mar;168(5):1059–73.

Wang RR, Gao YD, Ma CH, Zhang XJ, Huang CG, Huang JF, et al. Mangiferin, an anti-HIV-1 agent targeting protease and effective against resistant strains. Molecules. 2011 May;16(5):4264–77.

Wu W, Li R, Li X, He J, Jiang S, Liu S, et al. Quercetin as an antiviral agent inhibits influenza a virus (IAV) Entry. Viruses. 2015 Dec;8(1):1-18.

Carneiro BM, Batista MN, Braga ACS, Nogueira ML, Rahal P. The green tea molecule EGCG inhibits Zika virus entry. Virology. 2016 Sep;496:215–8.

Flobinus A, Taudon N, Desbordes M, Labrosse B, Simon F, Mazeron M-C, et al. Stability and antiviral activity against human cytomegalovirus of artemisinin derivatives. The Journal of Antimicrobial Chemotherapy. 2014 Jan;69(1):34–40.

Roy S, He R, Kapoor A, Forman M, Mazzone JR, Posner GH, et al. Inhibition of human cytomegalovirus replication by artemisinins: effects mediated through cell cycle modulation. Antimicrobial Agents and Chemotherapy. 2015 Jul;59(7):3870–9.

Isnawati A, Adelina R. Studi docking molekuler catechin gallate, epicatechin gallate, gallocatechin gallate, dan epigallocatechin gallate sebagai obat dislipidemia. Jurnal Kefarmasian Indonesia. 2015;5(1):25-32.

Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Current Computer Aided Drug Design. 2011 Jun;7(2):146–57.

Chang J, Schul W, Butters TD, Yip A, Liu B, Goh A, et al. Combination of alpha-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Research. 2011 Jan;89(1):26–34.

Wahala WMPB, Donaldson EF, Alwis R De, Loper MAA, Baric RS, Silva AM De. Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses. 2010;6(3):1–10.

Perera R, Kuhn RJ. Structural proteomics of dengue virus. Current Opinion in Microbiology. 2008 Aug;11(4):369–77.

Henderson BR, Saeedi BJ, Campagnola G, Geiss BJ. Analysis of RNA binding by the dengue virus NS5 RNA capping enzyme. PLoS One. 2011 Oct;6(10):1-9.

Christian EA, Kahle KM, Mattia K, Puffer BA, Pfaff JM, Miller A, et al. Atomic-level functional model of dengue virus envelope protein infectivity. Proceeding of The National Academy Sciences. 2013;110(46):1–6.